Abstract

The ISA Nomenclature Committee met electronically before and directly after the XVII ISA International Symposium on Amyloidosis, which, unfortunately, had to be virtual in September 2020 due to the ongoing COVID-19 pandemic instead of a planned meeting in Tarragona in March. In addition to confirmation of basic nomenclature, several additional concepts were discussed, which are used in scientific amyloid literature. Among such concepts are cytotoxic oligomers, protofibrils, primary and secondary nucleation, seeding and cross-seeding, amyloid signature proteins, and amyloid plaques. Recommendations for their use are given. Definitions of amyloid and amyloidosis are confirmed. Possible novel human amyloid fibril proteins, appearing as ‘classical’ in vivo amyloid, were discussed. It was decided to include fibulin-like extracellular matrix protein 1 (amyloid protein: AEFEMP1), which appears as localised amyloid in portal veins. There are several possible amyloid proteins under investigation, and these are included in a new Table.

摘要

ISA 命名委员会在第十七届 ISA 淀粉样变性国际研讨会之前和之后召开了电子会议，不幸的是，由于持续的 COVID-19 大流行，该研讨会不得不在 2020 年 9 月进行虚拟会议，而不是计划于 3 月在塔拉戈纳举行的会议。除了确认基本命名法外，还讨论了一些其他概念，这些概念用于科学淀粉样蛋白文献。这些概念包括细胞毒性寡聚体、原纤维、初级和次级成核、接种和交叉接种、淀粉样蛋白特征蛋白和淀粉样斑块。给出了它们的使用建议。确认了淀粉样蛋白和淀粉样变性的定义。可能的新型人类淀粉样原纤维蛋白，在体内表现为“经典”淀粉样蛋白，进行了讨论。决定包括纤维蛋白样细胞外基质蛋白 1（淀粉样蛋白：AEFEMP1），它在门静脉中表现为局部淀粉样蛋白。有几种可能的淀粉样蛋白正在研究中，这些都包含在一个新表中。